The global Integrase inhibitors market is comprised of pharmaceutical drugs that prevents HIV infection from permanently integrating into a host’s genetic material by inhibiting the integrase enzyme. Integrase inhibitors are often used in combination with other antiretroviral medications to control HIV and acquire viral suppression. Some widely used integrase inhibitors include raltegravir, elvitegravir, and dolutegravir. Effective retroviral therapy has improved the outcomes for people living with HIV/AIDS. Integrase inhibitors minimize drug resistance risks and have fewer side effects than older medications.
The global Integrase Inhibitors Market is estimated to be valued at US$ 33.8 billion in 2024 and is expected to exhibit a CAGR of 10.% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Increasing adoption of retroviral therapy: Rising adoption of combination antiretroviral therapy (cART) regimens for effective management of HIV is a key driver propelling the integrase inhibitors market growth. cART helps suppress the virus and reduces the risk of transmission to others. Integrase inhibitors are commonly used in first line cART due to their high genetic barrier to resistance. According to UNAIDS, around 27.5 million people were receiving cART globally in 2020, up from 7.8 million in 2010.
Focus on drug development: Emergence of drug resistant strains continues to pose challenges. To address this, manufacturers are investing in R&D to develop newer integrase inhibitors with improved resistance profiles. For instance, in August 2021, Merck received FDA approval for islatravir, a first-in-class oral integrase strand transfer inhibitor (INSTI) for HIV treatment and prevention. Such ongoing drug developments are fueling market expansion.
The global integrase inhibitors market is dominated by the HIV-1 infection sub-segment. HIV-1 is the most prevalent type that accounts for the majority of HIV infections worldwide. Integrase inhibitors are highly effective against HIV-1 and have better tolerance as compared to other antiretrovirals. Hence, they are widely prescribed for the treatment of HIV-1 infection.
Political: Government regulatory bodies across countries actively support research on HIV/AIDS treatment. They provide funding for clinical trials and new drug approvals related to integrase inhibitors.
Economic: Growing healthcare expenditure globally on HIV treatment is driving market growth. Developing countries receive funding support for procuring antiretroviral drugs.
Social: Non-governmental organizations spread awareness about effective management of HIV and treatment options. This has reduced social stigma related to the disease.
Technological: Advancements in drug delivery systems aid better patient adherence. Manufacturers focus on developing long-acting formulations with minimized dosing frequency.
Global Integrase Inhibitors Market Size is expected to witness high growth over the forecast period.
North America currently dominates the market due to extensive research, rising HIV prevalence and supportive reimbursement policies in the region. However, Asia Pacific is likely to emerge as the fastest growing market attributed to improving access to HIV care, increasing healthcare spending and expansion of local pharmaceutical companies in countries like India and China.
Key players operating in the integrase inhibitors market are Koninklijke TenCate (Netherlands), Low & Bonar (UK), Fibertex Nonwovens (Denmark), Thrace Group (Greece), Huesker (Germany), Berry Global (US), DuPont (US), Strata Systems (US), Leggett & Platt (US), Officine Maccaferri (Italy), GSE Environmental (US), Kaytech (South Africa), Mattex (Saudi Arabia), NAUE (Germany), Propex Operating Company (US), Carthage Mills (US), and Asahi Kasei Advance Corporation (Japan), among others.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it